Schreiber, A.; Ambrosy, B.; Planz, O.; Schloer, S.; Rescher, U.; Ludwig, S.
The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs. Pharmaceutics 2022, 14, 1776.
https://doi.org/10.3390/pharmaceutics14091776
AMA Style
Schreiber A, Ambrosy B, Planz O, Schloer S, Rescher U, Ludwig S.
The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs. Pharmaceutics. 2022; 14(9):1776.
https://doi.org/10.3390/pharmaceutics14091776
Chicago/Turabian Style
Schreiber, André, Benjamin Ambrosy, Oliver Planz, Sebastian Schloer, Ursula Rescher, and Stephan Ludwig.
2022. "The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs" Pharmaceutics 14, no. 9: 1776.
https://doi.org/10.3390/pharmaceutics14091776
APA Style
Schreiber, A., Ambrosy, B., Planz, O., Schloer, S., Rescher, U., & Ludwig, S.
(2022). The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs. Pharmaceutics, 14(9), 1776.
https://doi.org/10.3390/pharmaceutics14091776